Skip to Main Content

Paper Details

Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 <i>In Vitro</i> and SARS-CoV <i>In Vivo</i>.
J Virol
189
2020
COVID-19, MERS, MERS-, SARS, SARS-, SARS-CoV, SARS-CoV-2, Severe acute respiratory syndrome coronavirus, chloroquine, chlorpromazine, coronaviral, coronavirus, covid19, human, mice, mouse, patients
Author NameAffiliation
Stuart WestonUniversity of Maryland School of Medicine
James LogueUniversity of Maryland School of Medicine
Yize LiPerelman School of Medicine at the University of Pennsylvania
Matthew B FriemanUniversity of Maryland School of Medicine
Matthew B FriemanUniversity of Maryland School of Medicine
  • 1 - 5

Datasets

Release 1.2